Update on the use of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection
Fernández-Yunquera, A.; Rincón, D.; Salcedo, M.; Bañares, R.
Revista Espanola de Quimioterapia Publicacion Oficial de la Sociedad Espanola de Quimioterapia 26(3): 189-192
2013
ISSN/ISBN: 0214-3429 PMID: 24080883 Accession: 056777509
Full Text Article emailed within 1 workday: $29.90
Related References
Kanda, T.; Nakamoto, S.; Nakamura, M.; Jiang, X.; Miyamura, T.; Wu, S.; Yokosuka, O. 2014: Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection Journal of Clinical and Translational Hepatology 2(1): 1-6Goel, A.; Bhargava, R.; Rai, P.; Aggarwal, R. 2017: Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology 36(3): 227-234
Yang, J.; Rao, H.Y. 2018: Effectiveness and safety of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection Zhonghua Gan Zang Bing Za Zhi 26(3): 175-178
Maan, R.; van Tilborg, M.; Deterding, K.; Ramji, A.; van der Meer, A.J.; Wong, F.; Fung, S.; Sherman, M.; Manns, M.P.; Cornberg, M.; Hansen, B.E.; Wedemeyer, H.; Janssen, H.L.A.; de Knegt, R.J.; Feld, J.J. 2016: Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients with Chronic Hepatitis C Virus Infection and Cirrhosis Clinical Gastroenterology and Hepatology: the Official Clinical Practice Journal of the American Gastroenterological Association 14(12): 1821-1830.E6
Francis, A.K.; Beaudoin, F.L.; Naidjate, S.S.; Berard-Collins, C.; Zullo, A.R. 2020: Comparing Treatment Response Between Older and Younger Patients with Chronic Hepatitis C Virus Infection on Direct-acting Antiviral Agents Rhode Island Medical Journal 103(5): 35-40
Liu, C.-H.; Liu, C.-J.; Su, T.-H.; Fang, Y.-J.; Yang, H.-C.; Chen, P.-J.; Chen, D.-S.; Kao, J.-H. 2017: Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection Open Forum Infectious Diseases 4(1): Ofx028
Hunyady, B.él.; Kovács, B.áz.; Battyáni, Z. 2011: Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection Orvosi Hetilap 152(50): 1997-2009
Karimi-Sari, H.; Rezaee-Zavareh, M.S. 2020: Non-atherosclerotic cardiac manifestations of chronic hepatitis C virus infection in the era of direct-acting antiviral agents Atherosclerosis 298: 70
Conteduca, V.; Sansonno, D.; Russi, S.; Pavone, F.; Dammacco, F. 2014: Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents Journal of Infection 68(1): 1-20
Asselah, T; Marcellin, P; Schinazi, R F. 2018: Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure? Liver International 38: 7-13
Zanaga, L.P.; Miotto, N.; Mendes, L.C.; Stucchi, R.S.B.; Vigani, A.G. 2016: Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents Brazilian Journal of Medical and Biological Research 49(11): E5504
Asselah, T.; Marcellin, P.; Schinazi, R.F. 2018: Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure? Liver International: Official Journal of the International Association for the Study of the Liver 38(Suppl 1): 7-13
Welsch, C.; Jesudian, A.; Zeuzem, S.; Jacobson, I. 2012: New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives Gut 61(Suppl 1): I36-I46
Enomoto, M.; Tamori, A.; Murakami, Y.; Kawada, N. 2014: Interferon-α/β for treatment of chronic hepatitis C infection in the era of direct-acting antiviral agents Hepatology Research: the Official Journal of the Japan Society of Hepatology 44(4): 371-376
Johnson, P.J.; Berhane, S.; Walker, A.J.; Gordon, F.H.; Ryder, S.D.; McPherson, S.; Sreedharan, A.; Ustianowski, A.A.; Agarwal, K.; Mutimer, D.; Kumada, T.; Toyoda, H.; Irving, W.L.; Agarwal, K.; Aldersley, M.; Ala, A.; Aspinall, R.; Barnes, E.; Brown, A.; Corless, L.; Cramp, M.; Forton, D.; Foster, G.; Foxton, M.; Gelson, W.; Gorard, D.; Gordon, F.; Khakoo, S.; Lawson, A.; McPherson, S.; Moreea, S.; Mutimer, D.; Prince, M.; Richardson, P.; Rosenberg, W.; Ryder, S.; Sreedharan, A.; Stone, B.; Ustianowski, A.; Verma, S.; Wiselka, M. 2021: Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection Journal of Viral Hepatitis 28(1): 168-176
Bernstein, D.E. 2015: Roadblocks to Accessing Direct-Acting Antiviral Agents for Treatment of Hepatitis C Virus Infection Gastroenterology and Hepatology 11(5): 331-333
Xia, Y.; Liang, T.J. 2019: Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of Hepatitis B Virus Infection Gastroenterology 156(2): 311-324
Alghamdi, A.S.; Alqutub, A.; Abaalkhail, F.; Sanai, F.M.; Alghamdi, H.; Altraif, I.; Alswat, K.A.; Alghamdi, M.Y.; Babatin, M.A.; Alfaleh, F.Z. 2015: SASLT position statement on the direct-acting antiviral agents for the treatment of hepatitis C virus infection Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association 21(2): 60-63
Quer, J.; Buti, M.; Cubero, M.; Guardia, J.; Esteban, R.; Esteban, J.I. 2010: New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents Infection and Drug Resistance 3: 133-145
Poveda, E.; Wyles, D.L.; Mena, A.; Pedreira, Jé.D.; Castro-Iglesias, A.; Cachay, E. 2014: Update on hepatitis C virus resistance to direct-acting antiviral agents Antiviral Research 108: 181-191